Gavin P. Reynolds

Schizophrenia, antipsychotics and metabolic disease
J Psychopharmacol 2007 21: 355-356. [PDF] [References]  

A.H. Barnett, P. Mackin, I. Chaudhry, A. Farooqi, R. Gadsby, A. Heald, J. Hill, H. Millar, R. Peveler, A. Rees, V. Singh, D. TayLor, J. Vora, and P.B. Jones

Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia
J Psychopharmacol 2007 21: 357-373. [Abstract] [PDF] [References]  

S.L. de Haas, S.J. de Visser, J.P. van der Post, M. de Smet, R.C. Schoemaker, B. Rijnbeek, A.F. Cohen, J.M. Vega, N.G.B. Agrawal, T.V. Goel, R.C. Simpson, L.K. Pearson, S. Li, M. Hesney, M.G. Murphy, and J.M.A. van Gerven

Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA_{A 2,3} subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers
J Psychopharmacol 2007 21: 374-383. [Abstract] [PDF] [References]  

Rosa L. Fradley, Martin R. Guscott, Sharlene Bull, David J. Hallett, Simon C. Goodacre, Keith A. Wafford, ELizabeth M. Garrett, Richard J. Newman, Gillian F. O'Meara, Paul J. Whiting, Thomas W. Rosahl, Gerard R. Dawson, David S. Reynolds, and John R. Atack

Differential contribution of GABA_A receptor subtypes to the anticonvulsant efficacy of benzodiazepine site ligands
J Psychopharmacol 2007 21: 384-391. [Abstract] [PDF] [References]  

Beverley R. Twaites, Lynda V. Wilton, and Saad A. W. Shakir

The safety of quetiapine: results of a post-marketing surveillance study on 1728 patients in England
J Psychopharmacol 2007 21: 392-399. [Abstract] [PDF] [References]  

Maria A. Rettenbacher, Martina Hummer, ALex Hofer, Susanne Baumgartner, Christoph Ebenbichler, Monika EdLinger, Georg Kemmler, Monika Lechleitner, and W. Wolfgang Fleischhacker

Alterations of glucose metabolism during treatment with clozapine or amisulpride: results from a prospective 16-week study
J Psychopharmacol 2007 21: 400-404. [Abstract] [PDF] [References]  

G.D. Cooper, L.C. Pickavance, J.P.H. Wilding, J.A. HarroLd, J.C.G. HaLford, and A.J. Goudie

Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities
J Psychopharmacol 2007 21: 405-413. [Abstract] [PDF] [References]  

C. Neill Epperson, Zenab Amin, Frederick Naftolin, Angela Cappiello, Kathryn A. Czarkowski, Stephanie Stiklus, George M. Anderson, and John H. Krystal

The resistance to depressive relapse in menopausal women undergoing tryptophan depletion: preliminary findings
J Psychopharmacol 2007 21: 414-420. [Abstract] [PDF] [References]  

Bong-Ju Lee, Jung-Goo Lee, and Young-Hoon Kim

A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia
J Psychopharmacol 2007 21: 421-427. [Abstract] [PDF] [References]  

Xiangrong Zhang, Zhijun Zhang, Weirong Cheng, Xiaodong Mou, and Gavin P. Reynolds

The effect of chronic antipsychotic treatment on sexual behaviour, hormones and organ size in the male rat
J Psychopharmacol 2007 21: 428-434. [Abstract] [PDF] [References]  

Sophia Frangou, MichaeL Lewis, James Wollard, and Andrew Simmons

Preliminary in vivo evidence of increased N-acetyl-aspartate following eicosapentanoic acid treatment in patients with bipolar disorder
J Psychopharmacol 2007 21: 435-439. [Abstract] [PDF] [References]  

James M. Stone, Paul D. Morrison, and Lyn S. Pilowsky

Review: Glutamate and dopamine dysregulation in schizophrenia — a synthesis and selective review
J Psychopharmacol 2007 21: 440-452. [Abstract] [PDF] [References]  

Kanapathippillai Karunakaran, Tongeji E. Tungaraza, and Giles C. Harborne

Is clozapine—aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia?
J Psychopharmacol 2007 21: 453-456. [Abstract] [PDF] [References]  

To see an article, click its [PDF] link. To add articles to your marked citations, check the boxes to the left of the titles you want, and click the 'Add to Marked Citations' button. To see one abstract at a time, click its [Abstract] link.